Cipla

Cipla Ltd.
Mumbai Central
Mumbai 400 008

28th February 2013

To

(a) BSE Limited
Listing Department
P.J. Towers, Dalal Street
Mumbai 400 001

(b) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai 400 051

(c) SOCIETE DE LA BOURSE DE LUXEMBERG
Societe Anonyme
11, av de la Porte-Neuve,
L-2227 Luxemberg

Dear Sirs,

Please find enclosed copy of Press Release dated 28th February 2013.

Kindly acknowledge the receipt.

Thank you,

Yours faithfully,

For Cipla Limited

S. Radhakrishnan

Whole-time Director

Encl: as above

Phone : (9122) 23082891, 23095521 • Fax : (9122) 23070013, 23070393, 23070385

28 February 2013

On February 27, 2013, Cipla Limited ("Cipla") announced an offer to the shareholders of Cipla Medpro South Africa Ltd. ("Medpro") to acquire 100% of the ordinary share capital of Medpro for ZAR 10.0 per share (the "Offer"). The Offer will be implemented via a scheme of arrangement ("Scheme") and is subject to regulatory and other approvals including approval by Medpro shareholders. The Board of Directors of Medpro have unanimously resolved to support and facilitate Cipla's Offer and recommended to Medpro shareholders that they vote in favour of all resolutions required to implement the Scheme. The proposed acquisition will be made either directly by Cipla or by a subsidiary nominated by it and will be funded largely through internal accruals and will consider other alternatives, if required. The total consideration payable by Cipla is approximately USD 512 million or ZAR 4.5 billion[1].

Speaking of the Offer, Cipla CEO Mr. Subhanu Saxena said: "South Africa is an attractive emerging market with strong projected growth for generic drugs of approximately 14% per year for the next several years. This investment is aligned with Cipla's strategy to ascend the value-chain by managing a front-end sales force in a market outside India. Cipla and Medpro have enjoyed a long-standing symbiotic relationship spanning two decades. The deal enables Cipla to strengthen Medpro's position in the South African pharmaceutical market, support the optimisation of Medpro's manufacturing capability and support Medpro's expansion into collaboratively identified African markets."

Cipla Chairman, Dr. Yusuf Hamied added: "This investment is aimed at further strengthening our commitment to South Africa and the broader African continent. Patients and the healthcare landscape will benefit both from Cipla's 77+ years of experience across products, technologies, dosage forms and Cipla's ethos of striving hard to provide greater access to medicine."

Morgan Stanley is acting as exclusive financial advisor and Webber Wentzel is acting as legal advisor to Cipla in connection with this transaction.

About Medpro

Cipla Medpro is one of South Africa's fastest growing pharmaceutical companies. The third largest pharmaceutical firm in SA, it is a leading provider of chronic medicines to the public and private sectors, with particular strength within, inter alia, the cardiovascular, antiretroviral (ARV), respiratory and neuropsychiatric categories. Medpro has 2 distribution centers in Cape Town, one in Durbanville and one in Atlas Gardens. Medpro achieved ZAR 1,080 MM of revenues for H1 2012 (ZAR 1,768 MM for CY 2011) and ZAR 227 MM of EBITDA for H1 2012 (ZAR 594 MM for CY 2011). Cipla Medpro has a market capitalisation of more than R4 billion and 446.5 million ordinary shares in issue.

---

[1] Based on ordinary shares outstanding of approximately 446.5 MM and options outstanding of approximately 5.4 MM, converted to US$ using an exchange rate of 1 US$ = 8.829 ZAR as on February 26, 2013.

28 February 2013

Additional information can be found by visiting www.ciplamedsa.co.za

About Cipla

Cipla laid the foundation for the Indian pharmaceutical industry in 1935, with the vision to make India self-reliant in healthcare. Over the years, Cipla has emerged as one of the most respected names not just in India but worldwide. Its state-of-the-art R&D centre has given the country and the world many firsts. This includes the revolutionary AIDS cocktail for less than a dollar a day. The company has over 34 manufacturing facilities across India, and manufactures 2,000+ products in 65 therapeutic categories.

With a turnover of over US $ 1.4 billion, Cipla serves doctors and patients in over 170 countries. It has earned a name for maintaining one global standard across all its products and services. Cipla continues to support, improve and save millions of lives with its high-quality drugs and innovative devices.
Visit www.cipla.com

Cipla gives no assurance in relation to, and undertakes no obligation to publicly update or revise, any of the information or statements given in this release that may be (or may be deemed to be) forward looking.

Media Contact:

Finance
Ajay Luharuka
Contact No.: +91-22-23025435
E-Mail: ajay@cipla.com

Corporate Communications
Jaisingh Balakrishnan
Contact No: +91-22-23025813
E Mail: jaisingh.krishnan@cipla.com